Gene Editing Technologies in Diagnostic Platforms Market; by Technology (CRISPR, TALEN, ZFN, Others), by Application (Cell Line Engineering, Genetic Engineering, Others), by End User [Biotechnology & Pharmaceutical Companies, Academic and Research Institutions, Contract Research Organization (CROs)]; by Region (U.S., Canada, Mexico, Rest of North America, France, The UK, Spain, Germany, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America ) — Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019–2027
Market Overview/Industry Trends
Gene editing technologies in diagnostic platforms means adoption of gene editing in diagnostic platform to cure the diseases such as single-gene disorders such as cystic fibrosis, haemophilia, and sickle cell disease. Research is going on about gene editing to heal complex diseases such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infection, thereby expected to support the gene editing technologies in diagnostic platforms market growth.
The rise in the deoxyribonucleic acid (DNA) synthesis technology is driving growth of the gene editing technologies in diagnostic platforms market. CRISPR-Cas9 is a powerful genome editing tool. The demand for DNA synthesis technology is on the rise due to the development of CRISPR-Cas9. For example, Evonetix, a company based in Cambridge, U.K., is developing a silicon lab-on-chip system which is a desktop platform for highly equivalent, precise, and scalable DNA synthesis that will enlarge the horizons of synthetic biology.
Moreover, technological advancements in gene editing will further drive growth of the gene editing technologies in diagnostic platforms market. For example, a recent technological advancement in CRISPR can mutate entire DNA in one step. Earlier, CRISPR could only target single gene for editing. This new discovery will shorten the time gap to find the cure for deadly diseases.
However, these technological advancement can pose a big threat to individuals which may impede the growth of the gene editing technologies in diagnostic platforms market over the forecast period. For example, the simplicity and low-cost tools for gene editing will allow the amateurs or biohackers to perform their own experiments which will pose the potential risk from the release of genetically modified bugs. Moreover, the modification in the genes may harm the child as well as their future generations because the altered gene would be present in their sperm or eggs. Due to the related risks, mutating the human embryo and transplanting it to the women is banned in Britain. In November 2018, the Chinese team became the first in the world to edit human embryos. When they tried and failed to mutate the gene, it caused beta-thalassemia, a potentially fatal blood disorder. It was performed on the abnormal In vitro fertilization (IVF) embryos donated for research.
The use of genome editing in personalized medicine is likely to support the gene editing technologies in diagnostic platforms market growth during the forecast period. For example, the CRISPR-CAS9 system can be used to treat respiratory diseases as well as other ailments.
Moreover, gene editing is used to treat various complex ailments like cancer, blood disorders, blindness, acquired immune deficiency syndrome (AIDS), cystic fibrosis, Duchenne muscular dystrophy, Huntington’s disease, among others, which is difficult or nearly impossible to cure otherwise is driving the gene editing technologies in diagnostic platforms market growth in the near future.
However, gene therapy is very expensive which can impede growth of the gene editing technologies in diagnostic platforms market during the study period. For example, according to the news published on the Independent website, the cost of the therapy ranges from $500,000 to $1.5m and over a lifetime, drugs like nusinersen can be even more expensive which is about $750,000 in the first year followed by $375,000 in the second year for the lifetime.
In terms of revenue, the global gene editing technologies in diagnostic platforms market was valued at US$ 2,133.3 Mn in 2018 and is expected to reach US$ 7,004.8 Mn by 2027 growing at a CAGR of 14.4% over the forecast period. The study analyzes the market in terms of revenue across all the major regions, which has been further bifurcated into countries.
Gene Editing Technologies in Diagnostic Platforms Market Revenue & Forecast, (US$ Million), 2015 – 2027
Technology Outlook:
Based on technology, the gene editing technologies in the diagnostic platform market has been classified into CRISPR, TALEN, ZFN, and others. CRISPR segment held the largest share in 2018 and is expected to witness the fastest growth rate during the forecast period. CRISPR-Cas9 is the common, inexpensive and efficient system used for genome editing. It has the ability to mutate hundreds of genes simultaneously.
Application Outlook:
Based on application, the gene editing technologies in diagnostic platforms market has been classified into cell line engineering, genetic engineering and others (diagnostic and therapeutic). The genetic engineering segment is further bifurcated into animal genetic engineering and plant genetic engineering. The cell line engineering segment is expected to register the highest CAGR during the forecast period and also held the largest market share in 2018. Factors such as the growing industry focus on stem cell research, increasing funding from governments and private organizations, and growing awareness about stem cell therapies are driving this segment's growth.
End User Outlook:
Based on the end-user, the gene editing technologies in diagnostic platforms market is categorized into biotechnology and pharmaceutical companies, academic and government research institutes, and contract research organizations (CROs). The biotechnology and pharmaceutical companies segment will account for the largest share of gene editing technologies in diagnostic platforms market over next nine years due to the increasing incidence of infectious diseases and cancer are driving research activities across the globe. For example, according to an article published by the Centers for Disease Control and Prevention (CDC), it is expected that in the U.S., there will be more than 1 million cancer cases in men whereas 900,000 cases in women between 2010 to 2020. Types of cancer that are expected to grow in women are melanoma, lung, breast, uterine, and thyroid cancers whereas, in men melanoma, prostate, kidney, liver, and bladder cancers are expected to grow. Moreover, according to the World Health Organization (WHO), in 2018, 7.6 million people died from cancer which equals 13% of all deaths worldwide.
Regional Outlook:
In 2018, North America has the highest share in the gene editing technologies in diagnostic platforms market in 2018. Other factors such as the increasing prevalence of infectious diseases and cancer, and the increasing availability of research grants and funding are also helping this market's growth. However, Asia Pacific market is expected to grow at the highest CAGR during the forecast period. In Asia Pacific, China is a developed market for gene editing technologies in diagnostic platforms, whereas Japan and India are still the developing markets.
Competitive Landscape
The report provides both, qualitative and quantitative research of gene editing technologies in diagnostic platforms market, as well as provides comprehensive insights and development methods adopted by the key contenders. Beam Therapeutics, Bio-Connect Group, CRISPR Therapeutics, Editas Medicine, GeneCopoeia, Inc., GenScript, Horizon Discovery Ltd., Inscripta, Inc., Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs, OriGene Technologies, Inc., Pairwise, Precision Biosciences, Sangamo Therapeutics, STEMCELL Technologies Inc., Thermo Fisher Scientific Inc., Transposagen Biopharmaceuticals, Inc. are the key market participants operating in the gene editing technologies in diagnostic platforms market.
Gene Editing Technologies in Diagnostic Platforms Market:
- By Technology
- CRISPR
- TALEN
- ZFN
- Others
- By Application
- Cell Line Engineering
- Genetic Engineering
- Animal Genetic Engineering
- Plant Genetic Engineering
- Others
- By End User
- Biotechnology & Pharmaceutical Companies
- Academic and Research Institutions
- Contract Research Organization (CROs)
- By Geography
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2013 - 2017
1.2.2. Base
Year: 2018
1.2.3. Forecast
Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Gene Editing Technologies in Diagnostic
Platforms Market
6. Market Synopsis: Gene
Editing Technologies in Diagnostic Platforms Market
7. Gene Editing Technologies in Diagnostic Platforms Market
Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Gene Editing Technologies in Diagnostic Platforms Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Gene Editing Technologies in Diagnostic
Platforms Market
7.6. Porter’s
Five Force Analysis
7.7. PESTEL
Analysis
8. Global Gene Editing Technologies in Diagnostic Platforms
Market Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
8.2. Global
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
8.2.1. CRISPR
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2013 – 2018
8.2.1.3. Market
Forecast, 2019 – 2027
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2013 – 2018
8.2.1.5.1.2. Market
Forecast, 2019 – 2027
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2013 – 2018
8.2.1.5.2.2. Market
Forecast, 2019 – 2027
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2013 – 2018
8.2.1.5.3.2. Market
Forecast, 2019 – 2027
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2013 – 2018
8.2.1.5.4.2. Market
Forecast, 2019 – 2027
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2013 – 2018
8.2.1.5.5.2. Market
Forecast, 2019 – 2027
8.2.2. TALEN
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2013 – 2018
8.2.2.3. Market
Forecast, 2019 – 2027
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2013 – 2018
8.2.2.5.1.2. Market
Forecast, 2019 – 2027
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2013 – 2018
8.2.2.5.2.2. Market
Forecast, 2019 – 2027
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2013 – 2018
8.2.2.5.3.2. Market
Forecast, 2019 – 2027
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2013 – 2018
8.2.2.5.4.2. Market
Forecast, 2019 – 2027
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2013 – 2018
8.2.2.5.5.2. Market
Forecast, 2019 – 2027
8.2.3. ZFN
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2013 – 2018
8.2.3.3. Market
Forecast, 2019 – 2027
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2013 – 2018
8.2.3.5.1.2. Market
Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2013 – 2018
8.2.3.5.2.2. Market
Forecast, 2019 – 2027
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2013 – 2018
8.2.3.5.3.2. Market
Forecast, 2019 – 2027
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2013 – 2018
8.2.3.5.4.2. Market
Forecast, 2019 – 2027
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2013 – 2018
8.2.3.5.5.2. Market
Forecast, 2019 – 2027
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market
Estimation and Penetration, 2013 – 2018
8.2.4.3. Market
Forecast, 2019 – 2027
8.2.4.4. Compound
Annual Growth Rate (CAGR)
8.2.4.5. Regional
Bifurcation
8.2.4.5.1. North
America
8.2.4.5.1.1. Market
Estimation, 2013 – 2018
8.2.4.5.1.2. Market
Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market
Estimation, 2013 – 2018
8.2.4.5.2.2. Market
Forecast, 2019 – 2027
8.2.4.5.3. Asia
Pacific
8.2.4.5.3.1. Market
Estimation, 2013 – 2018
8.2.4.5.3.2. Market
Forecast, 2019 – 2027
8.2.4.5.4. Middle
East and Africa
8.2.4.5.4.1. Market
Estimation, 2013 – 2018
8.2.4.5.4.2. Market
Forecast, 2019 – 2027
8.2.4.5.5. Latin
America
8.2.4.5.5.1. Market
Estimation, 2013 – 2018
8.2.4.5.5.2. Market
Forecast, 2019 – 2027
8.3. Key Segment
for Channeling Investments
8.3.1. By
Technology
9. Global Gene Editing Technologies in Diagnostic Platforms
Market Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
9.2.1. Cell
Line Engineering
9.2.1.1. Definition
9.2.1.2. Market
Estimation and Penetration, 2013 – 2018
9.2.1.3. Market
Forecast, 2019 – 2027
9.2.1.4. Compound
Annual Growth Rate (CAGR)
9.2.1.5. Regional
Bifurcation
9.2.1.5.1. North
America
9.2.1.5.1.1. Market
Estimation, 2013 – 2018
9.2.1.5.1.2. Market
Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2013 – 2018
9.2.1.5.2.2. Market
Forecast, 2019 – 2027
9.2.1.5.3. Asia
Pacific
9.2.1.5.3.1. Market
Estimation, 2013 – 2018
9.2.1.5.3.2. Market
Forecast, 2019 – 2027
9.2.1.5.4. Middle
East and Africa
9.2.1.5.4.1. Market
Estimation, 2013 – 2018
9.2.1.5.4.2. Market
Forecast, 2019 – 2027
9.2.1.5.5. Latin
America
9.2.1.5.5.1. Market
Estimation, 2013 – 2018
9.2.1.5.5.2. Market
Forecast, 2019 – 2027
9.2.2. Genetic
Engineering (Definition, Market Estimation and Penetration, 2013 – 2018, Market
Estimation (2013 – 2018), Market Forecast (2019 – 2027), Compound Annual Growth
Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle
East and Africa, Latin America) and Information on Animal Genetic Engineering,
Plant Genetic Engineering)
9.2.2.1. Animal
Genetic Engineering
9.2.2.2. Plant
Genetic Engineering
9.2.3. Others
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2013 – 2018
9.2.3.3. Market
Forecast, 2019 – 2027
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2013 – 2018
9.2.3.5.1.2. Market
Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2013 – 2018
9.2.3.5.2.2. Market
Forecast, 2019 – 2027
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2013 – 2018
9.2.3.5.3.2. Market
Forecast, 2019 – 2027
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2013 – 2018
9.2.3.5.4.2. Market
Forecast, 2019 – 2027
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2013 – 2018
9.2.3.5.5.2. Market
Forecast, 2019 – 2027
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global Gene Editing Technologies in Diagnostic Platforms
Market Analysis and Forecasts, 2019 – 2027
10.1. Overview
10.2. Global
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
10.2.1. Biotechnology
and Pharmaceutical Companies
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2013 – 2018
10.2.1.3. Market
Forecast, 2019 – 2027
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2013 – 2018
10.2.1.5.1.2. Market
Forecast, 2019 – 2027
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2013 – 2018
10.2.1.5.2.2. Market
Forecast, 2019 – 2027
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2013 – 2018
10.2.1.5.3.2. Market
Forecast, 2019 – 2027
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2013 – 2018
10.2.1.5.4.2. Market
Forecast, 2019 – 2027
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2013 – 2018
10.2.1.5.5.2. Market
Forecast, 2019 – 2027
10.2.2. Academic
and Research Institutions
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2013 – 2018
10.2.2.3. Market
Forecast, 2019 – 2027
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2013 – 2018
10.2.2.5.1.2. Market
Forecast, 2019 – 2027
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2013 – 2018
10.2.2.5.2.2. Market
Forecast, 2019 – 2027
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2013 – 2018
10.2.2.5.3.2. Market
Forecast, 2019 – 2027
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2013 – 2018
10.2.2.5.4.2. Market
Forecast, 2019 – 2027
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2013 – 2018
10.2.2.5.5.2. Market
Forecast, 2019 – 2027
10.2.3. Contract
Research Organization (CROs)
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2013 – 2018
10.2.3.3. Market
Forecast, 2019 – 2027
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2013 – 2018
10.2.3.5.1.2. Market
Forecast, 2019 – 2027
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2013 – 2018
10.2.3.5.2.2. Market
Forecast, 2019 – 2027
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2013 – 2018
10.2.3.5.3.2. Market
Forecast, 2019 – 2027
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2013 – 2018
10.2.3.5.4.2. Market
Forecast, 2019 – 2027
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2013 – 2018
10.2.3.5.5.2. Market
Forecast, 2019 – 2027
10.3. Key
Segment for Channeling Investments
10.3.1. By End
User
11. North America Gene Editing Technologies in Diagnostic
Platforms Market Analysis and Forecasts, 2019 - 2027
11.1. Overview
11.1.1. North
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn)
11.2. North
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
11.2.1. CRISPR
11.2.2. TALEN
11.2.3. ZFN
11.2.4. Others
11.3. North
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
11.3.1. Cell
Line Engineering
11.3.2. Genetic
Engineering
11.3.2.1. Animal
Genetic Engineering
11.3.2.2. Plant
Genetic Engineering
11.3.3. Others
11.4. North
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
11.4.1. Biotechnology
and Pharmaceutical Companies
11.4.2. Academic
and Research Institutions
11.4.3. Contract
Research Organization (CROs)
11.5. North America
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
11.5.1.1.1. CRISPR
11.5.1.1.2. TALEN
11.5.1.1.3. ZFN
11.5.1.1.4. Others
11.5.1.2. U.S
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.1.2.1. Cell
Line Engineering
11.5.1.2.2. Genetic
Engineering
11.5.1.2.2.1. Animal
Genetic Engineering
11.5.1.2.2.2. Plant
Genetic Engineering
11.5.1.2.3. Others
11.5.1.3. U.S
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
11.5.1.3.1. Biotechnology
and Pharmaceutical Companies
11.5.1.3.2. Academic
and Research Institutions
11.5.1.3.3. Contract
Research Organization (CROs)
11.5.2. Canada
11.5.2.1. Canada
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
11.5.2.1.1. CRISPR
11.5.2.1.2. TALEN
11.5.2.1.3. ZFN
11.5.2.1.4. Others
11.5.2.2. Canada
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.2.2.1. Cell
Line Engineering
11.5.2.2.2. Genetic
Engineering
11.5.2.2.2.1. Animal
Genetic Engineering
11.5.2.2.2.2. Plant
Genetic Engineering
11.5.2.2.3. Others
11.5.2.3. Canada
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
11.5.2.3.1. Biotechnology
and Pharmaceutical Companies
11.5.2.3.2. Academic
and Research Institutions
11.5.2.3.3. Contract
Research Organization (CROs)
11.5.3. Mexico
11.5.3.1. Mexico
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
11.5.3.1.1. CRISPR
11.5.3.1.2. TALEN
11.5.3.1.3. ZFN
11.5.3.1.4. Others
11.5.3.2. Mexico
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
11.5.3.2.1. Cell
Line Engineering
11.5.3.2.2. Genetic
Engineering
11.5.3.2.2.1. Animal
Genetic Engineering
11.5.3.2.2.2. Plant
Genetic Engineering
11.5.3.2.3. Others
11.5.3.3. Mexico
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
11.5.3.3.1. Biotechnology
and Pharmaceutical Companies
11.5.3.3.2. Academic
and Research Institutions
11.5.3.3.3. Contract
Research Organization (CROs)
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Technology
11.5.4.1.1. CRISPR
11.5.4.1.2. TALEN
11.5.4.1.3. ZFN
11.5.4.1.4. Others
11.5.4.2. Rest
of North America Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Application
11.5.4.2.1. Cell
Line Engineering
11.5.4.2.2. Genetic
Engineering
11.5.4.2.2.1. Animal
Genetic Engineering
11.5.4.2.2.2. Plant
Genetic Engineering
11.5.4.2.3. Others
11.5.4.3. Rest
of North America Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By End User
11.5.4.3.1. Biotechnology
and Pharmaceutical Companies
11.5.4.3.2. Academic
and Research Institutions
11.5.4.3.3. Contract
Research Organization (CROs)
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Technology
11.6.3. By
Application
11.6.4. By End
User
12. Europe Gene Editing Technologies in Diagnostic Platforms
Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Europe
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
12.2. Europe
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
12.2.1. CRISPR
12.2.2. TALEN
12.2.3. ZFN
12.2.4. Others
12.3. Europe
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
12.3.1. Cell
Line Engineering
12.3.2. Genetic
Engineering
12.3.2.1. Animal
Genetic Engineering
12.3.2.2. Plant
Genetic Engineering
12.3.3. Others
12.4. Europe
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
12.4.1. Biotechnology
and Pharmaceutical Companies
12.4.2. Academic
and Research Institutions
12.4.3. Contract
Research Organization (CROs)
12.5. Europe
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Country
12.5.1. France
12.5.1.1. France
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
12.5.1.1.1. CRISPR
12.5.1.1.2. TALEN
12.5.1.1.3. ZFN
12.5.1.1.4. Others
12.5.1.2. France
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.1.2.1. Cell
Line Engineering
12.5.1.2.2. Genetic
Engineering
12.5.1.2.2.1. Animal
Genetic Engineering
12.5.1.2.2.2. Plant
Genetic Engineering
12.5.1.2.3. Others
12.5.1.3. France
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.1.3.1. Biotechnology
and Pharmaceutical Companies
12.5.1.3.2. Academic
and Research Institutions
12.5.1.3.3. Contract
Research Organization (CROs)
12.5.2. The UK
12.5.2.1. The
UK Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Technology
12.5.2.1.1. CRISPR
12.5.2.1.2. TALEN
12.5.2.1.3. ZFN
12.5.2.1.4. Others
12.5.2.2. The
UK Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.2.2.1. Cell
Line Engineering
12.5.2.2.2. Genetic
Engineering
12.5.2.2.2.1. Animal
Genetic Engineering
12.5.2.2.2.2. Plant
Genetic Engineering
12.5.2.2.3. Others
12.5.2.3. The
UK Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By End User
12.5.2.3.1. Biotechnology
and Pharmaceutical Companies
12.5.2.3.2. Academic
and Research Institutions
12.5.2.3.3. Contract
Research Organization (CROs)
12.5.3. Spain
12.5.3.1. Spain
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
12.5.3.1.1. CRISPR
12.5.3.1.2. TALEN
12.5.3.1.3. ZFN
12.5.3.1.4. Others
12.5.3.2. Spain
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.3.2.1. Cell
Line Engineering
12.5.3.2.2. Genetic
Engineering
12.5.3.2.2.1. Animal
Genetic Engineering
12.5.3.2.2.2. Plant
Genetic Engineering
12.5.3.2.3. Others
12.5.3.3. Spain
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.3.3.1. Biotechnology
and Pharmaceutical Companies
12.5.3.3.2. Academic
and Research Institutions
12.5.3.3.3. Contract
Research Organization (CROs)
12.5.4. Germany
12.5.4.1. Germany
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
12.5.4.1.1. CRISPR
12.5.4.1.2. TALEN
12.5.4.1.3. ZFN
12.5.4.1.4. Others
12.5.4.2. Germany
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.4.2.1. Cell
Line Engineering
12.5.4.2.2. Genetic
Engineering
12.5.4.2.2.1. Animal
Genetic Engineering
12.5.4.2.2.2. Plant
Genetic Engineering
12.5.4.2.3. Others
12.5.4.3. Germany
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.4.3.1. Biotechnology
and Pharmaceutical Companies
12.5.4.3.2. Academic
and Research Institutions
12.5.4.3.3. Contract
Research Organization (CROs)
12.5.5. Italy
12.5.5.1. Italy
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
12.5.5.1.1. CRISPR
12.5.5.1.2. TALEN
12.5.5.1.3. ZFN
12.5.5.1.4. Others
12.5.5.2. Italy
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
12.5.5.2.1. Cell
Line Engineering
12.5.5.2.2. Genetic
Engineering
12.5.5.2.2.1. Animal
Genetic Engineering
12.5.5.2.2.2. Plant
Genetic Engineering
12.5.5.2.3. Others
12.5.5.3. Italy
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
12.5.5.3.1. Biotechnology
and Pharmaceutical Companies
12.5.5.3.2. Academic
and Research Institutions
12.5.5.3.3. Contract
Research Organization (CROs)
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
12.5.6.1.1. CRISPR
12.5.6.1.2. TALEN
12.5.6.1.3. ZFN
12.5.6.1.4. Others
12.5.6.2. Nordic
Countries Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
12.5.6.2.1. Cell
Line Engineering
12.5.6.2.2. Genetic
Engineering
12.5.6.2.2.1. Animal
Genetic Engineering
12.5.6.2.2.2. Plant
Genetic Engineering
12.5.6.2.3. Others
12.5.6.3. Nordic
Countries Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
12.5.6.3.1. Biotechnology
and Pharmaceutical Companies
12.5.6.3.2. Academic
and Research Institutions
12.5.6.3.3. Contract
Research Organization (CROs)
12.5.6.4. Nordic
Countries Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Technology
12.5.7.1.1. CRISPR
12.5.7.1.2. TALEN
12.5.7.1.3. ZFN
12.5.7.1.4. Others
12.5.7.2. Benelux
Union Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Application
12.5.7.2.1. Cell
Line Engineering
12.5.7.2.2. Genetic
Engineering
12.5.7.2.2.1. Animal
Genetic Engineering
12.5.7.2.2.2. Plant
Genetic Engineering
12.5.7.2.3. Others
12.5.7.3. Benelux
Union Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By End User
12.5.7.3.1. Biotechnology
and Pharmaceutical Companies
12.5.7.3.2. Academic
and Research Institutions
12.5.7.3.3. Contract
Research Organization (CROs)
12.5.7.4. Benelux
Union Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
12.5.8.1.1. CRISPR
12.5.8.1.2. TALEN
12.5.8.1.3. ZFN
12.5.8.1.4. Others
12.5.8.2. Rest
of Europe Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
12.5.8.2.1. Cell
Line Engineering
12.5.8.2.2. Genetic
Engineering
12.5.8.2.2.1. Animal
Genetic Engineering
12.5.8.2.2.2. Plant
Genetic Engineering
12.5.8.2.3. Others
12.5.8.3. Rest
of Europe Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
12.5.8.3.1. Biotechnology
and Pharmaceutical Companies
12.5.8.3.2. Academic
and Research Institutions
12.5.8.3.3. Contract
Research Organization (CROs)
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Technology
12.6.3. By
Application
12.6.4. By End
User
13. Asia Pacific Gene Editing Technologies in Diagnostic
Platforms Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Asia
Pacific Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn)
13.2. Asia
Pacific Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
13.2.1. CRISPR
13.2.2. TALEN
13.2.3. ZFN
13.2.4. Others
13.3. Asia
Pacific Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
13.3.1. Cell
Line Engineering
13.3.2. Genetic
Engineering
13.3.2.1. Animal
Genetic Engineering
13.3.2.2. Plant
Genetic Engineering
13.3.3. Others
13.4. Asia
Pacific Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
13.4.1. Biotechnology
and Pharmaceutical Companies
13.4.2. Academic
and Research Institutions
13.4.3. Contract
Research Organization (CROs)
13.5. Asia
Pacific Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
13.5.1.1.1. CRISPR
13.5.1.1.2. TALEN
13.5.1.1.3. ZFN
13.5.1.1.4. Others
13.5.1.2. China
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.1.2.1. Cell
Line Engineering
13.5.1.2.2. Genetic
Engineering
13.5.1.2.2.1. Animal
Genetic Engineering
13.5.1.2.2.2. Plant
Genetic Engineering
13.5.1.2.3. Others
13.5.1.3. China
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
13.5.1.3.1. Biotechnology
and Pharmaceutical Companies
13.5.1.3.2. Academic
and Research Institutions
13.5.1.3.3. Contract
Research Organization (CROs)
13.5.2. Japan
13.5.2.1. Japan
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
13.5.2.1.1. CRISPR
13.5.2.1.2. TALEN
13.5.2.1.3. ZFN
13.5.2.1.4. Others
13.5.2.2. Japan
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.2.2.1. Cell
Line Engineering
13.5.2.2.2. Genetic
Engineering
13.5.2.2.2.1. Animal
Genetic Engineering
13.5.2.2.2.2. Plant
Genetic Engineering
13.5.2.2.3. Others
13.5.2.3. Japan
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
13.5.2.3.1. Biotechnology
and Pharmaceutical Companies
13.5.2.3.2. Academic
and Research Institutions
13.5.2.3.3. Contract
Research Organization (CROs)
13.5.3. India
13.5.3.1. India
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
13.5.3.1.1. CRISPR
13.5.3.1.2. TALEN
13.5.3.1.3. ZFN
13.5.3.1.4. Others
13.5.3.2. India
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.3.2.1. Cell
Line Engineering
13.5.3.2.2. Genetic
Engineering
13.5.3.2.2.1. Animal
Genetic Engineering
13.5.3.2.2.2. Plant
Genetic Engineering
13.5.3.2.3. Others
13.5.3.3. India
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
13.5.3.3.1. Biotechnology
and Pharmaceutical Companies
13.5.3.3.2. Academic
and Research Institutions
13.5.3.3.3. Contract
Research Organization (CROs)
13.5.4. New
Zealand
13.5.4.1. New
Zealand Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
13.5.4.1.1. CRISPR
13.5.4.1.2. TALEN
13.5.4.1.3. ZFN
13.5.4.1.4. Others
13.5.4.2. New
Zealand Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
13.5.4.2.1. Cell
Line Engineering
13.5.4.2.2. Genetic
Engineering
13.5.4.2.2.1. Animal
Genetic Engineering
13.5.4.2.2.2. Plant
Genetic Engineering
13.5.4.2.3. Others
13.5.4.3. New
Zealand Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
13.5.4.3.1. Biotechnology
and Pharmaceutical Companies
13.5.4.3.2. Academic
and Research Institutions
13.5.4.3.3. Contract
Research Organization (CROs)
13.5.5. Australia
13.5.5.1. Australia
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
13.5.5.1.1. CRISPR
13.5.5.1.2. TALEN
13.5.5.1.3. ZFN
13.5.5.1.4. Others
13.5.5.2. Australia
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
13.5.5.2.1. Cell
Line Engineering
13.5.5.2.2. Genetic
Engineering
13.5.5.2.2.1. Animal
Genetic Engineering
13.5.5.2.2.2. Plant
Genetic Engineering
13.5.5.2.3. Others
13.5.5.3. Australia
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
13.5.5.3.1. Biotechnology
and Pharmaceutical Companies
13.5.5.3.2. Academic
and Research Institutions
13.5.5.3.3. Contract
Research Organization (CROs)
13.5.6. South
Korea
13.5.6.1. South
Korea Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Technology
13.5.6.1.1. CRISPR
13.5.6.1.2. TALEN
13.5.6.1.3. ZFN
13.5.6.1.4. Others
13.5.6.2. South
Korea Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.6.2.1. Cell
Line Engineering
13.5.6.2.2. Genetic
Engineering
13.5.6.2.2.1. Animal
Genetic Engineering
13.5.6.2.2.2. Plant
Genetic Engineering
13.5.6.2.3. Others
13.5.6.3. South
Korea Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By End User
13.5.6.3.1. Biotechnology
and Pharmaceutical Companies
13.5.6.3.2. Academic
and Research Institutions
13.5.6.3.3. Contract
Research Organization (CROs)
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Technology
13.5.7.1.1. CRISPR
13.5.7.1.2. TALEN
13.5.7.1.3. ZFN
13.5.7.1.4. Others
13.5.7.2. Southeast
Asia Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.7.2.1. Cell
Line Engineering
13.5.7.2.2. Genetic
Engineering
13.5.7.2.2.1. Animal
Genetic Engineering
13.5.7.2.2.2. Plant
Genetic Engineering
13.5.7.2.3. Others
13.5.7.3. Southeast
Asia Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By End User
13.5.7.3.1. Biotechnology
and Pharmaceutical Companies
13.5.7.3.2. Academic
and Research Institutions
13.5.7.3.3. Contract
Research Organization (CROs)
13.5.7.4. Southeast
Asia Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn)
and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Technology
13.5.8.1.1. CRISPR
13.5.8.1.2. TALEN
13.5.8.1.3. ZFN
13.5.8.1.4. Others
13.5.8.2. Rest
of Asia Pacific Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Application
13.5.8.2.1. Cell
Line Engineering
13.5.8.2.2. Genetic
Engineering
13.5.8.2.2.1. Animal
Genetic Engineering
13.5.8.2.2.2. Plant
Genetic Engineering
13.5.8.2.3. Others
13.5.8.3. Rest
of Asia Pacific Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By End User
13.5.8.3.1. Biotechnology
and Pharmaceutical Companies
13.5.8.3.2. Academic
and Research Institutions
13.5.8.3.3. Contract
Research Organization (CROs)
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Technology
13.6.3. By
Application
13.6.4. By End
User
14. Middle East and Africa Gene Editing Technologies in
Diagnostic Platforms Market Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Middle
East and Africa Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn)
14.2. Middle
East and Africa Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Technology
14.2.1. CRISPR
14.2.2. TALEN
14.2.3. ZFN
14.2.4. Others
14.3. Middle
East and Africa Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Application
14.3.1. Cell
Line Engineering
14.3.2. Genetic
Engineering
14.3.2.1. Animal
Genetic Engineering
14.3.2.2. Plant
Genetic Engineering
14.3.3. Others
14.4. Middle
East and Africa Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By End User
14.4.1. Biotechnology
and Pharmaceutical Companies
14.4.2. Academic
and Research Institutions
14.4.3. Contract
Research Organization (CROs)
14.5. Middle
East and Africa Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
14.5.1.1.1. CRISPR
14.5.1.1.2. TALEN
14.5.1.1.3. ZFN
14.5.1.1.4. Others
14.5.1.2. Saudi
Arabia Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
14.5.1.2.1. Cell
Line Engineering
14.5.1.2.2. Genetic
Engineering
14.5.1.2.2.1. Animal
Genetic Engineering
14.5.1.2.2.2. Plant
Genetic Engineering
14.5.1.2.3. Others
14.5.1.3. Saudi
Arabia Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
14.5.1.3.1. Biotechnology
and Pharmaceutical Companies
14.5.1.3.2. Academic
and Research Institutions
14.5.1.3.3. Contract
Research Organization (CROs)
14.5.2. UAE
14.5.2.1. UAE
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
14.5.2.1.1. CRISPR
14.5.2.1.2. TALEN
14.5.2.1.3. ZFN
14.5.2.1.4. Others
14.5.2.2. UAE
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.2.2.1. Cell
Line Engineering
14.5.2.2.2. Genetic
Engineering
14.5.2.2.2.1. Animal
Genetic Engineering
14.5.2.2.2.2. Plant
Genetic Engineering
14.5.2.2.3. Others
14.5.2.3. UAE
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
14.5.2.3.1. Biotechnology
and Pharmaceutical Companies
14.5.2.3.2. Academic
and Research Institutions
14.5.2.3.3. Contract
Research Organization (CROs)
14.5.3. Egypt
14.5.3.1. Egypt
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
14.5.3.1.1. CRISPR
14.5.3.1.2. TALEN
14.5.3.1.3. ZFN
14.5.3.1.4. Others
14.5.3.2. Egypt
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.3.2.1. Cell
Line Engineering
14.5.3.2.2. Genetic
Engineering
14.5.3.2.2.1. Animal
Genetic Engineering
14.5.3.2.2.2. Plant
Genetic Engineering
14.5.3.2.3. Others
14.5.3.3. Egypt
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
14.5.3.3.1. Biotechnology
and Pharmaceutical Companies
14.5.3.3.2. Academic
and Research Institutions
14.5.3.3.3. Contract
Research Organization (CROs)
14.5.4. Kuwait
14.5.4.1. Kuwait
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
14.5.4.1.1. CRISPR
14.5.4.1.2. TALEN
14.5.4.1.3. ZFN
14.5.4.1.4. Others
14.5.4.2. Kuwait
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.4.2.1. Cell
Line Engineering
14.5.4.2.2. Genetic
Engineering
14.5.4.2.2.1. Animal
Genetic Engineering
14.5.4.2.2.2. Plant
Genetic Engineering
14.5.4.2.3. Others
14.5.4.3. Kuwait
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
14.5.4.3.1. Biotechnology
and Pharmaceutical Companies
14.5.4.3.2. Academic
and Research Institutions
14.5.4.3.3. Contract
Research Organization (CROs)
14.5.5. South
Africa
14.5.5.1. South
Africa Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
14.5.5.1.1. CRISPR
14.5.5.1.2. TALEN
14.5.5.1.3. ZFN
14.5.5.1.4. Others
14.5.5.2. South
Africa Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
14.5.5.2.1. Cell
Line Engineering
14.5.5.2.2. Genetic
Engineering
14.5.5.2.2.1. Animal
Genetic Engineering
14.5.5.2.2.2. Plant
Genetic Engineering
14.5.5.2.3. Others
14.5.5.3. South
Africa Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
14.5.5.3.1. Biotechnology
and Pharmaceutical Companies
14.5.5.3.2. Academic
and Research Institutions
14.5.5.3.3. Contract
Research Organization (CROs)
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa Gene Editing Technologies in Diagnostic Platforms
Market Revenue (US$ Mn) and Forecasts, By Technology
14.5.6.1.1. CRISPR
14.5.6.1.2. TALEN
14.5.6.1.3. ZFN
14.5.6.1.4. Others
14.5.6.2. Rest
of Middle East & Africa Gene Editing Technologies in Diagnostic Platforms
Market Revenue (US$ Mn) and Forecasts, By Application
14.5.6.2.1. Cell
Line Engineering
14.5.6.2.2. Genetic
Engineering
14.5.6.2.2.1. Animal
Genetic Engineering
14.5.6.2.2.2. Plant
Genetic Engineering
14.5.6.2.3. Others
14.5.6.3. Rest
of Middle East & Africa Gene Editing Technologies in Diagnostic Platforms
Market Revenue (US$ Mn) and Forecasts, By End User
14.5.6.3.1. Biotechnology
and Pharmaceutical Companies
14.5.6.3.2. Academic
and Research Institutions
14.5.6.3.3. Contract
Research Organization (CROs)
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Technology
14.6.3. By
Application
14.6.4. By End
User
15. Latin America Gene Editing Technologies in Diagnostic
Platforms Market Analysis and Forecasts, 2019 - 2027
15.1. Overview
15.1.1. Latin
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn)
15.2. Latin
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Technology
15.2.1. CRISPR
15.2.2. TALEN
15.2.3. ZFN
15.2.4. Others
15.3. Latin
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Application
15.3.1. Cell
Line Engineering
15.3.2. Genetic
Engineering
15.3.2.1. Animal
Genetic Engineering
15.3.2.2. Plant
Genetic Engineering
15.3.3. Others
15.4. Latin
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By End User
15.4.1. Biotechnology
and Pharmaceutical Companies
15.4.2. Academic
and Research Institutions
15.4.3. Contract
Research Organization (CROs)
15.5. Latin
America Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$
Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
15.5.1.1.1. CRISPR
15.5.1.1.2. TALEN
15.5.1.1.3. ZFN
15.5.1.1.4. Others
15.5.1.2. Brazil
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.1.2.1. Cell
Line Engineering
15.5.1.2.2. Genetic
Engineering
15.5.1.2.2.1. Animal
Genetic Engineering
15.5.1.2.2.2. Plant
Genetic Engineering
15.5.1.2.3. Others
15.5.1.3. Brazil
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
15.5.1.3.1. Biotechnology
and Pharmaceutical Companies
15.5.1.3.2. Academic
and Research Institutions
15.5.1.3.3. Contract
Research Organization (CROs)
15.5.2. Argentina
15.5.2.1. Argentina
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Technology
15.5.2.1.1. CRISPR
15.5.2.1.2. TALEN
15.5.2.1.3. ZFN
15.5.2.1.4. Others
15.5.2.2. Argentina
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By Application
15.5.2.2.1. Cell
Line Engineering
15.5.2.2.2. Genetic
Engineering
15.5.2.2.2.1. Animal
Genetic Engineering
15.5.2.2.2.2. Plant
Genetic Engineering
15.5.2.2.3. Others
15.5.2.3. Argentina
Gene Editing Technologies in Diagnostic Platforms Market Revenue (US$ Mn) and
Forecasts, By End User
15.5.2.3.1. Biotechnology
and Pharmaceutical Companies
15.5.2.3.2. Academic
and Research Institutions
15.5.2.3.3. Contract
Research Organization (CROs)
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Technology
15.5.3.1.1. CRISPR
15.5.3.1.2. TALEN
15.5.3.1.3. ZFN
15.5.3.1.4. Others
15.5.3.2. Rest
of Latin America Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By Application
15.5.3.2.1. Cell
Line Engineering
15.5.3.2.2. Genetic
Engineering
15.5.3.2.2.1. Animal
Genetic Engineering
15.5.3.2.2.2. Plant
Genetic Engineering
15.5.3.2.3. Others
15.5.3.3. Rest
of Latin America Gene Editing Technologies in Diagnostic Platforms Market
Revenue (US$ Mn) and Forecasts, By End User
15.5.3.3.1. Biotechnology
and Pharmaceutical Companies
15.5.3.3.2. Academic
and Research Institutions
15.5.3.3.3. Contract
Research Organization (CROs)
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Technology
15.6.3. By
Application
15.6.4. By End
User
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2018
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Beam
Therapeutics
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Bio-Connect
Group
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. CRISPR
Therapeutics
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. Editas
Medicine
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. GeneCopoeia,
Inc.
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. GenScript
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key
Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. Horizon
Discovery Ltd.
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Inscripta,
Inc.
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Integrated
DNA Technologies, Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Intellia
Therapeutics, Inc.
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Lonza
Group Ltd.
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Merck
KGaA
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. New
England Biolabs
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. OriGene
Technologies, Inc.
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business
Strategies
17.15. Pairwise
17.15.1. Company
Details
17.15.2. Company
Overview
17.15.3. Product
Offerings
17.15.4. Key
Developments
17.15.5. Financial
Analysis
17.15.6. SWOT
Analysis
17.15.7. Business
Strategies
17.16. Precision
Biosciences
17.16.1. Company
Details
17.16.2. Company
Overview
17.16.3. Product
Offerings
17.16.4. Key
Developments
17.16.5. Financial
Analysis
17.16.6. SWOT Analysis
17.16.7. Business
Strategies
17.17. Sangamo
Therapeutics
17.17.1. Company
Details
17.17.2. Company
Overview
17.17.3. Product
Offerings
17.17.4. Key
Developments
17.17.5. Financial
Analysis
17.17.6. SWOT
Analysis
17.17.7. Business
Strategies
17.18. STEMCELL
Technologies Inc.
17.18.1. Company
Details
17.18.2. Company
Overview
17.18.3. Product
Offerings
17.18.4. Key
Developments
17.18.5. Financial
Analysis
17.18.6. SWOT
Analysis
17.18.7. Business
Strategies
17.19. Thermo
Fisher Scientific Inc.
17.19.1. Company
Details
17.19.2. Company
Overview
17.19.3. Product
Offerings
17.19.4. Key
Developments
17.19.5. Financial
Analysis
17.19.6. SWOT
Analysis
17.19.7. Business
Strategies
17.20. Transposagen
Biopharmaceuticals, Inc.
17.20.1. Company
Details
17.20.2. Company
Overview
17.20.3. Product
Offerings
17.20.4. Key
Developments
17.20.5. Financial
Analysis
17.20.6. SWOT
Analysis
17.20.7. Business
Strategies
17.21. Other
Market Participants
18. Key Findings
Note: This ToC is tentative and can
be changed according to the research study conducted during the course of
report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
